The Global Health program at the Council on Foreign Relations (CFR) provides independent, evidence-based analysis and recommendations to help policymakers, business leaders, journalists, and the public meet the health challenges of a globalized world.
These challenges include infectious diseases that cross borders with easier trade and travel, the rapid growth of noncommunicable diseases in working-age people in developing countries, and the emerging perils of antibiotic resistance and climate change. These changing health needs place new demands on international institutions and initiatives at a time when their long-term financing is in doubt.
Through rigorous research, articles, and online-interactives, CFR's experts work to advance evidence-based analysis and informed decision-making in global health.
During its fifteen years, PEPFAR has become one of the most important global health initiatives ever launched. However, its influence is fading, threatening the global fight against HIV/AIDS as the struggle against the pandemic faces a turning point.
The WHO’s tobacco treaty in 2005 was hailed as a crucial tool for controlling one of the world’s most lethal substances and as a model for confronting other global health problems. Ten years later it is a qualified success, write CFR’s Thomas J. Bollyky and David P. Fidler.
To continue the extraordinary progress of the past fifteen years, the next U.S. administration should further integrate global health, development, and pandemic preparedness into the U.S. national security architecture.
To contain infectious disease outbreaks like Zika and Ebola, global health authorities must learn from past efforts to motivate the private and nonprofit sectors around problems of the poor, write CFR’s Thomas Bollyky and PATH CEO Steve Davis.
The special exemptions for tobacco products in the TPP trade deal say less about cross-border investment rules generally, and more about the unique nature of tobacco under U.S. and international law, writes CFR’s Thomas Bollyky.